The present invention relates to the use of subunits and oligomers of mannan-binding lectin (MBL) in prophylactic and/or curative treatment of infections in an individual receiving TNF-inhibiting treatment, in particular TNF-.alpha.-inhibiting treatment. The MBL may be administered together with an antimicrobial agent, for example as a kit-of-parts.